Adalimumab biosimilar - EPIRUS Biopharmaceuticals

Drug Profile

Adalimumab biosimilar - EPIRUS Biopharmaceuticals

Alternative Names: adalimumab mAb - EPIRUS; BOW 050

Latest Information Update: 09 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EPIRUS Biopharmaceuticals
  • Class Anti-TNF monoclonal antibodies
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Autoimmune disorders

Most Recent Events

  • 25 Jul 2016 EPIRUS Biopharmaceuticals files for Chapter 7 bankruptcy (Epirus Biopharmaceuticals 8-K, July 2016)
  • 15 Mar 2016 EPIRUS Biopharmaceuticals announces intention to submit regulatory application gloablly in 2018
  • 16 Nov 2015 EPIRUS plans a phase III trial for Autoimmune disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top